John K. Buolamwini - Publications

Pharmaceutical Sciences University of Tennessee Health Science Center, Memphis, TN, United States 
Pharmaceutical Chemistry

66 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 9. PMID 32630235 DOI: 10.3390/cells9071592  0.4
2019 Wang C, Buolamwini JK. A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker. Experimental Hematology & Oncology. 8: 18. PMID 31440421 DOI: 10.1186/s40164-019-0144-y  0.4
2018 Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK. QSAR Studies of New Pyrido[3,4-]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Medicinal Chemistry Research : An International Journal For Rapid Communications On Design and Mechanisms of Action of Biologically Active Agents. 27: 2466-2481. PMID 31360052 DOI: 10.1007/s00044-018-2250-5  0.4
2018 Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R. Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Frontiers in Pharmacology. 9: 5. PMID 29387014 DOI: 10.3389/fphar.2018.00005  0.4
2017 Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents. Drug Designing : Open Access. 6. PMID 29354330 DOI: 10.4172/2169-0138.1000143  0.4
2015 Nag S, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Buolamwini JK, Wang W, Zhang R. Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography : Bmc. 29: 654-63. PMID 25294254 DOI: 10.1002/bmc.3327  0.96
2014 Playa H, Lewis TA, Ting A, Suh BC, Muñoz B, Matuza R, Passer BJ, Schreiber SL, Buolamwini JK. Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). Bioorganic & Medicinal Chemistry Letters. 24: 5801-4. PMID 25454272 DOI: 10.1016/j.bmcl.2014.10.026  0.96
2014 Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH, Wang H, Buolamwini JK, Zhang R. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications. 5: 5086. PMID 25271708 DOI: 10.1038/ncomms6086  0.96
2014 Nag S, Qin JJ, Patil S, Deokar H, Buolamwini JK, Wang W, Zhang R. A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 969: 235-40. PMID 25195025 DOI: 10.1016/j.jchromb.2014.08.030  0.96
2014 Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology. 147: 893-902.e2. PMID 25016295 DOI: 10.1053/j.gastro.2014.07.001  0.96
2013 Chen Q, Buolamwini JK, Smith JC, Li A, Xu Q, Cheng X, Wei D. Impact of resistance mutations on inhibitor binding to HIV-1 integrase. Journal of Chemical Information and Modeling. 53: 3297-307. PMID 24205814 DOI: 10.1021/ci400537n  0.96
2013 Sharma H, Sanchez TW, Neamati N, Detorio M, Schinazi RF, Cheng X, Buolamwini JK. Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 6146-51. PMID 24091080 DOI: 10.1016/j.bmcl.2013.09.009  0.96
2013 Wang C, Lin W, Playa H, Sun S, Cameron K, Buolamwini JK. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochemical Pharmacology. 86: 1531-40. PMID 24021350 DOI: 10.1016/j.bcp.2013.08.063  0.96
2013 Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK. Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 437-47. PMID 23447563 DOI: 10.1158/1940-6207.CAPR-12-0345  0.96
2013 Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C, Chen X. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochemical Pharmacology. 85: 1246-56. PMID 23415900 DOI: 10.1016/j.bcp.2013.02.003  0.96
2012 Yang X, Wang W, Qin JJ, Wang MH, Sharma H, Buolamwini JK, Wang H, Zhang R. JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. Plos One. 7: e34303. PMID 22558087 DOI: 10.1371/journal.pone.0034303  0.96
2012 Sharma H, Cheng X, Buolamwini JK. Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors. Journal of Chemical Information and Modeling. 52: 515-44. PMID 22256860 DOI: 10.1021/ci200485a  0.96
2012 Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway (Journal of Biological Chemistry (2008) 283, (8624-8633)) Journal of Biological Chemistry. 287: 23850. DOI: 10.1074/jbc.A112.707860  0.96
2011 Lin W, Buolamwini JK. Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probe. Bioconjugate Chemistry. 22: 1221-7. PMID 21539390 DOI: 10.1021/bc2000758  0.96
2011 Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK. Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 19: 2030-45. PMID 21371895 DOI: 10.1016/j.bmc.2011.01.047  0.96
2011 Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Molecular Cancer Therapeutics. 10: 69-79. PMID 21075910 DOI: 10.1158/1535-7163.MCT-10-0581  0.96
2010 Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Research. 70: 3890-5. PMID 20424118 DOI: 10.1158/0008-5472.CAN-10-0155  0.96
2010 Wang C, Pimple S, Buolamwini JK. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochemical Pharmacology. 79: 307-20. PMID 19735647 DOI: 10.1016/j.bcp.2009.08.028  0.96
2009 Gupte A, Buolamwini JK. Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 917-21. PMID 19097778 DOI: 10.1016/j.bmcl.2008.11.112  0.96
2009 Gupte A, Buolamwini JK. CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). Bioorganic & Medicinal Chemistry Letters. 19: 314-8. PMID 19091561 DOI: 10.1016/j.bmcl.2008.11.092  0.96
2008 Hevener KE, Ball DM, Buolamwini JK, Lee RE. Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic & Medicinal Chemistry. 16: 8042-53. PMID 18701298 DOI: 10.1016/j.bmc.2008.07.070  0.96
2008 Zhu Z, Buolamwini JK. Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorganic & Medicinal Chemistry. 16: 3848-65. PMID 18289860 DOI: 10.1016/j.bmc.2008.01.044  0.96
2008 Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. The Journal of Biological Chemistry. 283: 8624-33. PMID 18218619 DOI: 10.1074/jbc.M707860200  0.96
2007 Gupte A, Buolamwini JK. Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors. Bioorganic & Medicinal Chemistry. 15: 7726-37. PMID 17881236 DOI: 10.1016/j.bmc.2007.08.058  0.96
2007 Lin W, Buolamwini JK. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. Journal of Medicinal Chemistry. 50: 3906-20. PMID 17636949 DOI: 10.1021/jm070311l  0.96
2007 Zhu Z, Hofmann PA, Buolamwini JK. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology. 292: H2921-6. PMID 17293492 DOI: 10.1152/ajpheart.01191.2005  0.96
2007 Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 15: 1212-28. PMID 17158051 DOI: 10.1016/j.bmc.2006.11.026  0.96
2006 Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Research Reviews. 26: 569-94. PMID 16788977 DOI: 10.1002/med.20070  0.96
2006 Patil S, Buolamwini JK. Recent uses of palladium chemistry in indole synthesis Current Organic Synthesis. 3: 477-498. DOI: 10.2174/157017906778699495  0.96
2006 Buolamwini JK. A Survey of Novel Molecular Targets for Anticancer Drug Discovery Novel Anticancer Agents. 1-35. DOI: 10.1016/B978-012088561-9/50002-8  0.96
2006 Adjei AA, Buolamwini JK. Preface Novel Anticancer Agents. DOI: 10.1016/B978-012088561-9/50001-6  0.96
2005 Gupte A, Buolamwini JK, Yadav V, Chu CK, Naguib FN, el Kouni MH. 6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es). Biochemical Pharmacology. 71: 69-73. PMID 16310172 DOI: 10.1016/j.bcp.2005.10.031  0.96
2005 Buolamwini JK, Kamath S. Molecule-kinase interaction map. Nature Biotechnology. 23: 1346; author reply 1. PMID 16273056 DOI: 10.1038/nbt1105-1346a  0.96
2005 Kamath SA, Buolamwini JK. Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site. Journal of Computer-Aided Molecular Design. 19: 287-91. PMID 16184431 DOI: 10.1007/s10822-005-5083-5  0.96
2005 Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, Buolamwini JK, Houghton PJ. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. The Journal of Biological Chemistry. 280: 31924-35. PMID 16009706 DOI: 10.1074/jbc.M507057200  0.96
2005 Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Current Cancer Drug Targets. 5: 57-68. PMID 15720190 DOI: 10.2174/1568009053332672  0.96
2004 Addo JK, Buolamwini JK. Design, synthesis, and evaluation of 5'-S-aminoethyl-N(6)- azidobenzyl-5'-thioadenosine biotin conjugate: a bifunctional photoaffinity probe for the es nucleoside transporter. Bioconjugate Chemistry. 15: 536-40. PMID 15149181 DOI: 10.1021/bc034165j  0.96
2004 Gupte A, Buolamwini JK. Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors. Bioorganic & Medicinal Chemistry Letters. 14: 2257-60. PMID 15081020 DOI: 10.1016/j.bmcl.2004.02.016  0.96
2004 Kuo CL, Assefa H, Kamath S, Brzozowski Z, Slawinski J, Saczewski F, Buolamwini JK, Neamati N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 47: 385-99. PMID 14711310 DOI: 10.1021/jm030378i  0.96
2003 Assefa H, Kamath S, Buolamwini JK. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Journal of Computer-Aided Molecular Design. 17: 475-93. PMID 14703120 DOI: 10.1023/B:JCAM.0000004622.13865.4f  0.96
2003 Kamath S, Buolamwini JK. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. Journal of Medicinal Chemistry. 46: 4657-68. PMID 14561085 DOI: 10.1021/jm030065n  0.96
2003 Buolamwini JK, Assefa H. Overview of novel anticancer drug targets. Methods in Molecular Medicine. 85: 3-28. PMID 12710193 DOI: 10.1385/1-59259-380-1:03  0.96
2003 Zhu Z, Furr J, Buolamwini JK. Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter. Journal of Medicinal Chemistry. 46: 831-7. PMID 12593662 DOI: 10.1021/jm020405p  0.96
2002 Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. Journal of Medicinal Chemistry. 45: 841-52. PMID 11831895 DOI: 10.1021/jm010399h  0.96
2001 Bedir E, Calis I, Dunbar C, Sharan R, Buolamwini JK, Khan IA. Two novel cycloartane-type triterpene glycosides from the roots of Astragalus prusianus Tetrahedron. 57: 5961-5966. DOI: 10.1016/S0040-4020(01)00607-X  0.96
2001 Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics Current Cancer Drug Targets. 1: 177-196.  0.96
2000 Weinstein JN, Buolamwini JK. Molecular targets in cancer drug discovery: Cell-based profiling Current Pharmaceutical Design. 6: 473-483. PMID 10788592  0.96
2000 Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery Current Pharmaceutical Design. 6: 379-392. PMID 10788588  0.96
2000 Buolamwini JK. Molecular targets for novel anticancer drug discovery: Preface Current Pharmaceutical Design. 6.  0.96
1999 Buolamwini JK. Novel anticancer drug discovery Current Opinion in Chemical Biology. 3: 500-509. PMID 10419854 DOI: 10.1016/S1367-5931(99)80073-8  0.96
1999 Raghavan K, Kahn SD, Buolamwini JK. Building a hypothesis for nucleotide transport inhibitors Acs Symposium Series. 719: 153-164.  0.96
1997 Kombian SB, Saleh TM, Fiagbe NI, Chen X, Akabutu JJ, Buolamwini JK, Pittman QJ. Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro. Brain Research Bulletin. 44: 603-10. PMID 9365804 DOI: 10.1016/S0361-9230(97)00284-0  0.96
1997 Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN. A protein expression database for the molecular pharmacology of cancer Electrophoresis. 18: 647-653. PMID 9150955 DOI: 10.1002/elps.1150180351  0.96
1997 Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Van Osdol WW, Monks AP, Scudiero DA, Sausville EA, et al. An information-intensive approach to the molecular pharmacology of cancer Science. 275: 343-349. PMID 8994024 DOI: 10.1126/science.275.5298.343  0.96
1997 Buolamwini JK, Barchi JJ. Solution NMR conformational analysis of the potent equilibrative sensitive (ES) nucleoside transporter inhibitor, S6-(4- nitrobenzyl)mercaptopurine riboside (NBMPR) Nucleosides and Nucleotides. 16: 2101-2110.  0.96
1997 Zjawiony JK, Khalil AA, Clark AM, Hufford CD, Buolamwini JK. Studies on Methoxylation in the 7H-Naphtho[1,2,3-i,j] [2,7]naphthyridin-7-one System Journal of Heterocyclic Chemistry. 34: 1233-1237.  0.96
1997 Buolamwini JK. Nucleoside transport inhibitors: Structure-activity relationships and potential therapeutic applications Current Medicinal Chemistry. 4: 35-66.  0.96
1996 Buolamwini JK, Raghavan K, Fesen MR, Pommier Y, Kohn KW, Weinstein JN. Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors Pharmaceutical Research. 13: 1892-1895. PMID 8987091 DOI: 10.1023/A:1016005813432  0.96
1995 Raghavan K, Buolamwini JK, Fesen MR, Pommier Y, Kohn KW, Weinstein JN. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: A comparative molecular field analysis (CoMFA) study Journal of Medicinal Chemistry. 38: 890-897. PMID 7699704  0.96
1994 Buolamwini JK, Craik JD, Wiley JS, Robins MJ, Gati WP, Cass CE, Paterson ARP. Conjugates of fluorescein and SAENTA (5'-S-(2-aminoethyl)-N6-(4- nitrobenzyl)-5'-thioadenosine): Flow cytometry probes for the es nucleoside transporter elements of the plasma membrane Nucleosides and Nucleotides. 13: 737-751. DOI: 10.1080/15257779408013276  0.96
1993 Jamieson GP, Brocklebank AM, Snook MB, Sawyer WH, Buolamwini JK, Paterson ARP, Wiley JS. Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells Cytometry. 14: 32-38. PMID 8432200 DOI: 10.1002/cyto.990140107  0.96
Show low-probability matches.